Trial Profile
HEXVIX VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2021
Price :
$35
*
At a glance
- Drugs Hexyl aminolevulinate (Primary) ; Mitomycin; Mitomycin
- Indications Bladder cancer
- Focus Diagnostic use
- Acronyms HELENA
- 05 Feb 2021 This trial has been completed in Germany, according to European Clinical Trials Database record. (Global end date:2020-10-30)
- 10 Nov 2012 Planned end date changed from 8 Sep 2011 to 8 Jan 2015 as reported by European Clinical Trials Database.
- 15 Jun 2011 New trial record